HELPLINE
MESOTHELIOMA NEWS
Scroll to find news of interest to you, or search by category. The Mesothelioma Applied Research Foundation covers mesothelioma news for patients and their families. Our write-ups are heavily reliant on peer-reviewed medical research studies with input from mesothelioma experts from around the world but are also accessible to non-medical readers.
A Phase 3 trial in relapsed mesothelioma patients showed a significant improvement in overall survival and progression-free survival when patients were treated with nivolumab. Nivolumab
The Mesothelioma Applied Research Foundation is pleased to announce the addition of five new members to the organization’s board of directors. Jessica Blackford-Cleeton – Springfield, Illinois Cheryl Bruner, Esq. – Louisville, Kentucky Randy Krocka – Sheet
This MesoTV panel of four mesothelioma patients and one caregiver discuss survivors’ guilt and other issues affecting mesothelioma survivors. Chris DeSantis Heather Von St James
Today, the Mesothelioma Applied Research Foundation, among 130 organizations, cancer centers, and other institutions, sent a letter to President Joseph R. Biden, key members of
The Congressionally Directed Medical Research Programs’ (CDMPR), Rare Cancers Research Program (RCRP) consumer advocate Jessica Blackford-Cleeton recently participated in the evaluation of research applications submitted
Marjorie G. Zauderer, MD, discusses a currently enrolling Phase 1 clinical trial for mesothelioma patients. This CAR-T cell therapy trial targets mesothelin, a protein heavily
Heather Von St James’ fifteenth annual Lung Leavin’ Day is virtually taking place Saturday, Feb. 6 to celebrate her 15 years of survivorship. Folks can join via Facebook
Kanwal Raghav, MD, discusses the results of a Phase 2 trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma. Dr.